Advertisement
Advertisement
AVXL
Anavex Life Sciences
4.53
USDSponsored
-0.23
-4.94%
Mar 06, 12:59 UTC -5
Open
AVXL Earnings Reports
Positive Surprise Ratio
AVXL beat 25 of 37 last estimates.
68%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.07
Implied change from Q1 26 (Revenue/ EPS)
--
/+16.67%
Implied change from Q2 25 (Revenue/ EPS)
--
/-46.15%
Anavex Life Sciences earnings per share and revenue
On Feb 09, 2026, AVXL reported earnings of -0.06 USD per share (EPS) for Q1 26, beating the estimate of -0.11 USD, resulting in a 46.52% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +6.10% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of -0.07 USD, with revenue projected to reach -- USD, implying an increase of 16.67% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.62
Actual
-$0.92
Surprise
-47.84%
CorMedix Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.83
Actual
$0.61
Surprise
-26.73%
Keros Therapeutics, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.64
Actual
-$0.86
Surprise
-34.10%
REGENXBIO Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.97
Actual
-$1.30
Surprise
-33.31%
Lexicon Pharmaceuticals, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.04
Surprise
+43.18%
Contineum Therapeutics, Inc. Class A Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.41
Actual
-$0.49
Surprise
-18.41%
Lineage Cell Therapeutics, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.05
Actual
$0.00
Surprise
+100.00%
Atea Pharmaceuticals, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.54
Actual
-$0.56
Surprise
-5.44%
Liquidia Corporation Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.18
Actual
$0.15
Surprise
-18.48%
Aligos Therapeutics, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$1.88
Actual
-$1.91
Surprise
-1.11%
FAQ
What were Anavex Life Sciences's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Anavex Life Sciences reported EPS of -$0.06, beating estimates by 46.52%, and revenue of $0.00, 0% as expectations.
How did the market react to Anavex Life Sciences's Q1 2026 earnings?
The stock price moved up 6.1%, changed from $4.10 before the earnings release to $4.35 the day after.
When is Anavex Life Sciences expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Anavex Life Sciences's next earnings report?
Based on 5
analysts, Anavex Life Sciences is expected to report EPS of -$0.07 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement